首页|期刊导航|中医肿瘤学杂志|经导管动脉化疗栓塞术联合扶正消瘤颗粒治疗原发性肝癌的近期疗效分析

经导管动脉化疗栓塞术联合扶正消瘤颗粒治疗原发性肝癌的近期疗效分析OA

Transcatheter Arterial Chemoembolization Combined with Fuzheng Xiaoliu Granules for Primary Liver Cancer:A Short-Term Efficacy Analysis

中文摘要英文摘要

目的 探讨经导管动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)联合扶正消瘤颗粒治疗原发性肝癌的近期疗效.方法 纳入82例肝细胞癌患者,随机分为对照组和治疗组,每组患者41例.两组均给予对症基础治疗,其中治疗组方案为TACE联合扶正消瘤颗粒Ⅱ号方(每日2次),对照组给予TACE及西医内科综合治疗.比较两组患者术后1个月、术后3个月客观缓解率(objective response rate,ORR)、甲胎蛋白(alpha-fetoprotein,AFP)、卡氏功能状态(Karnofsky performance status,KPS)评分、肝功能相关指标.结果 术后3个月对照组、治疗组客观缓解率(objective response rate,ORR)分别为48.8%、70.7%,差异有统计学意义(P<0.05).术后3个月治疗组AFP下降幅度优于对照组,差异有统计学意义(P<0.05).术后1个月及术后3个月对照组、治疗组KPS评分均高于术前1天,且治疗组上升幅度优于对照组,差异有统计学意义(P<0.05).术后3个月对照组、治疗组丙氨酸氨基转移酶(alanine aminotransferase,ALT)、天门冬氨酸氨基转移酶(aspartate aminotransferase,AST)、总胆红素(total bilirubin,TBIL)水平与术前1天及术后1个月相比降低,且治疗组降幅优于对照组,差异有统计学意义(P<0.05).术后3个月对照组、治疗组白蛋白(albumin,ALB)水平与术前1天及术后1个月相比升高,且治疗组涨幅优于对照组,差异有统计学意义(P<0.05).两组不良反应发生率比较,差异无统计学意义(P>0.05).结论 TACE联合扶正消瘤颗粒能提高肝癌患者的客观缓解率,改善肝功能,提高生活质量,效果优于单纯常规西医治疗.

Objective To evaluate the short-term efficacy of transcatheter arterial chemoembolization(TACE)combined with Fuzheng Xiaoliu Granules in the treatment of primary liver cancer.Methods A total of 82 patients with hepatocellular carcinoma were prospectively enrolled and randomly assigned to a control group(n=41)and a treatment group(n=41).Both groups received standard symptomatic treatment.The treatment group received TACE combined with Fuzheng Xiaoliu Granules Ⅱ(twice daily),while the control group received TACE and conventional Western medical treatment.The objective response rate(ORR),alpha-fetoprotein(AFP)level,Karnofsky performance status(KPS)score,and liver function parameters were compared between the two groups at 1 month and 3 months post-treatment.Results At 3 months post-treatment,the ORR was 48.8%in the control group and 70.7%in the treatment group,with a statistically significant difference(P<0.05).The reduction in AFP level at 3 months post-treatment was significantly greater in the treatment group than that in the control group(P<0.05).The KPS scores at 1 month and 3 months post-treatment were significantly higher in both groups compared with baseline(the preoperative day),with a greater increase in the treatment group(P<0.05).At 3 months post-treatment,the levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),and total bilirubin(TBIL)decreased in both groups compared with baseline and 1-month post-treatment levels,with a greater reduction in the treatment group(P<0.05).Albumin(ALB)levels increased in both groups at 3 months post-treatment compared with baseline and 1-month post-treatment levels,and the increase was greater in the treatment group(P<0.05).There was no significant difference in the incidence of adverse events between the two groups(P>0.05).Conclusion TACE combined with Fuzheng Xiaoliu Granules can improve the objective response rate,liver function,and quality of life in patients with hepatocellular carcinoma,demonstrating superior efficacy compared with conventional Western medical treatment alone.

李雪静;刘欣;张德政;栗辉;李娅;韩康平;詹鹏超;李臻;高源;李鑫;吴白露;叶书文;陈欣菊;韦超

郑州大学第一附属医院放射介入科,河南 郑州 450052北京科技大学计算机与通信工程学院,北京 100083北京科技大学计算机与通信工程学院,北京 100083北京科技大学计算机与通信工程学院,北京 100083郑州大学第一附属医院消化内科,河南 郑州 450052天津医科大学医学技术学院,天津 300203河南省直第三人民医院医学影像科,河南 郑州 450000郑州大学第一附属医院放射介入科,河南 郑州 450052河南中医药大学中医药科学院,河南 郑州 450000郑州大学第一附属医院放射介入科,河南 郑州 450052郑州大学第一附属医院放射介入科,河南 郑州 450052郑州大学第一附属医院放射介入科,河南 郑州 450052河南中医药大学第一附属医院脾胃肝胆科,河南 郑州 450052河南中医药大学第一附属医院脾胃肝胆科,河南 郑州 450052

医药卫生

化疗栓塞肝细胞癌扶正消瘤颗粒肝功能介入治疗

chemoembolizationhepatocellular carcinomaFuzheng Xiaoliu Granulesliver functioninterventional therapy

《中医肿瘤学杂志》 2026 (4)

42-47,6

河南省重点研发专项(编号:241111311000)河南省"三个100"计划:医学科技人才海外研修项目(编号:HNMOT2025078)河南省自然科学基金重点科学基金项目(编号:232300421120).

10.19811/j.cnki.ISSN2096-6628.2026.07.006

评论